Save
Share
Cite
Information from Industry June 30, 2020
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
Vol 86 • 2025 • Number 1
Read the Current Issue
Brief Report
Sex Differences in PTSD among US Military Veterans
Commentary
The Opioid Industry's Legacy: A Generation of Prescribed Suffering
Clinical and Practical Psychopharmacology
Cannabis Use in Pregnancy and ASD or ADHD in Offspring
Commentary
Evolving Care and Research Priorities in ADHD
Original Research
Treatments and Treatment Predictors in Patients With SUDs and ADHD
Systematic Review
Efficacy and Safety of Memantine for Children and Adults with ADHD
Related Articles
Information from Industry
Auvelity: A Rapid-Acting Antidepressant With Multimodal Activity
September 27, 2024
AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY...
